Biogen Idec (NQ:BIIB)

Performance

52-Week Range 1.5% below 52-week high

250.69

138.0052W Low 254.4152W High

1 Week 1.5% below 1-week high

231.041W Low 254.411W High

Biogen Idec (BIIB) traded between $138.00 and $254.41 over the past 52 weeks and last traded at $250.69, 1.5% below its 52-week high. Over the past week it ranged between $231.04 and $254.41.

Past 12 Months

+7.4%

+10.2%

+24.0%

+36.0%

+41.0%

+67.0%

1W +$17.21

1M +$23.16

3M +$48.50

6M +$66.31

YTD +$72.87

1Y +$100.61

BIIB was +67.0% over the past year, +36.0% over six months, +41.0% year to date, +7.4% in the last week.

12 Months vs Market

BIIB

+67.0%

DIA

+11.6%

SPY

+13.1%

QQQ

+15.4%

IWM

+11.9%

Over the past 12 months BIIB returned +67.0% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 1.12× 3-mo avg

Today 1,157,377 3-mo avg 1.0M

1.3M

1.0M

1.1M

YTD

1.2M

1.4M

BIIB most recently traded 1,157,377 shares against a 3-month average daily volume of 1.0M.

More News

Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

October 14, 2026

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

Discover which S&P500 stocks are making waves on Monday. ↗

October 12, 2026

Via Chartmill

October 12, 2026

Via Chartmill

Biogen (BIIB) Stock Is Up, What You Need To Know

October 12, 2026

2 Surging Stocks for Long-Term Investors and 1 We Brush Off

October 12, 2026

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)

October 07, 2026

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

October 02, 2026

From Biogen Inc.

1 Profitable Stock Worth Investigating and 2 We Ignore

October 01, 2026

Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks

September 30, 2026

Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack

September 24, 2026

Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

September 23, 2026

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

September 21, 2026

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

September 17, 2026

From Biogen Inc.

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗

September 15, 2026

Via MarketBeat

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology ↗

September 12, 2026

Via MarketBeat

Thursday's session: top gainers and losers in the S&P500 index ↗

September 10, 2026

Via Chartmill

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

September 09, 2026

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

September 08, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial

September 08, 2026

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

September 08, 2026

From BioMedWire